-

Sphere Fluidics and ClexBio introduce CYTRIX Microfluidic Hydrogel Kit

First in Sphere Fluidics’ new range of 3D cell culture kits in partnership with ClexBio

CAMBRIDGE, England & OSLO, Norway--(BUSINESS WIRE)--Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and ClexBio, a pioneer in solutions for tissue engineering and single-cell techniques, today announced the launch of the biocompatible CYTRIX Microfluidic Hydrogel Kit. The kit combines ClexBio’s novel CYTRIX Hydrogel with Sphere Fluidics’ specially designed Pico-Gen™ double aqueous biochip to allow the plug-and-play generation of defined, reproducible and tailorable hydrogel microstructures for 3D cell culture, organoids, single-cell analysis, and many other applications. This allows researchers to study valuable cells over many weeks rather than days in defined microenvironments that mimic the natural extracellular matrix.

The CYTRIX Hydrogel overcomes the challenges of existing microfluidic hydrogel formation techniques, such as clogging, finicky temperature control or time-critical mixing procedures. It offers cytocompatibility and microfluidic-optimized gelation kinetics, providing researchers with a cell-friendly solution to reduce the effect of harmful temperatures, pH changes and use of UV-light required for existing hydrogel formation techniques. Paired with the Sphere Fluidics Pico-Gen double aqueous biochip and microfluidics, the CYTRIX Hydrogel enables efficient encapsulation of mammalian cells, bacteria, and other microorganisms in a homogeneous and defined extracellular matrix that supports cell viability.

Dr. Xin Li, Associate Director of Science at Sphere Fluidics said: “The CYTRIX Microfluidic Hydrogel Kit mimics the 3D microenvironment and help researchers explore the potential of hydrogel-based microfluidics in tissue engineering, drug discovery and regenerative medicine over many weeks.”

Dr. Armend Håti, CEO and Co-Founder of ClexBio said: “This exciting collaboration with Sphere Fluidics has enabled us to deliver one of the first commercial solutions that allows simple and cell-friendly formation of cell-laden microgels, lengthening the time that researchers can study the contents of microspheres.”

For further information about the CYTRIX Microfluidic Hydrogel Kit, please visit: https://spherefluidics.com/microfluidic-hydrogel/

Contacts

Zyme Communications
Dr. Michelle Ricketts
Tel: +44 (0)7789 053 885
Email: michelle.ricketts@zymecommunications.com

Sphere Fluidics


Release Versions

Contacts

Zyme Communications
Dr. Michelle Ricketts
Tel: +44 (0)7789 053 885
Email: michelle.ricketts@zymecommunications.com

More News From Sphere Fluidics

Sphere Fluidics Rebrands to Sphere Bio

CAMBRIDGE, England--(BUSINESS WIRE)--Sphere Fluidics today announced its rebranding to Sphere Bio. The name change marks a significant milestone in the Company’s development, reflecting its transition from a leading droplet-based microfluidics innovator to an established commercial provider of integrated life sciences tools and solutions. Founded in 2010, the Company has been focused on the development of novel single-cell analysis products and R&D services for a growing portfolio of market...

Sphere Fluidics Launches Cyto-Mine Chroma and Announces Early Access Program

CAMBRIDGE, England--(BUSINESS WIRE)--Sphere Fluidics, a leading provider of innovative picodroplet-based microfluidics solutions for functional single cell analysis and isolation, today announced the launch of Cyto-Mine® Chroma and the opening of its Early Access Program at SLAS2025 International Conference and Exhibition in San Diego. Cyto-Mine Chroma represents the next generation of Sphere Fluidics’ industry-leading Cyto-Mine single-cell analysis platform. The Early Access Program provides a...

Sphere Fluidics Strengthens Global Commercial Teams and Establishes Direct Sales and Support Channel in North America

CAMBRIDGE, England--(BUSINESS WIRE)--Sphere Fluidics, a leading provider of innovative droplet-based microfluidics solutions for functional profiling of single cells at scale, today announced a significant expansion of its global commercial presence. The Company has established a new direct sales and support channel for customers in North America and made several commercial leadership changes globally. These milestones reflect the ongoing strategic focus on operational scale-up to address deman...
Back to Newsroom